Filing Flows › Xenetic Biosciences (XBIO) › Q2 2025
Xenetic Biosciences (XBIO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Xenetic Biosciences (XBIO) reported revenue of $590K for the second quarter 2025 (Q2 2025), -19% from a year earlier and -0.6% from the quarter before. Operating margin was -122.8%, net loss $689K (116.7% of revenue).
Xenetic Biosciences, Q2 2025: revenue $590K (-19% year over year), operating margin -122.8%, net loss $689K, operating cash flow −$384K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $590K | -0.6% | -19% |
| Operating profit | −$724K | — | — |
| Net earnings | −$689K | — | — |
| Operating cash flow | −$384K | — | — |
What changed
Revenue was $590K in Q2 2025, down 19% year over year and down 1% from the previous quarter.
Operating costs exceeded revenue by $724K, an operating margin of -122.8%. Total costs fell 36% while revenue fell 19%. The quarter ended with a net loss of $689K, narrower than the previous quarter's $903K loss.
Operating cash flow was −$384K. Non-cash charges added back $16K of share-based compensation. Working capital and other items added $289K.
Questions
What was Xenetic Biosciences' revenue in the second quarter 2025?
Xenetic Biosciences (XBIO) reported revenue of $590K for the second quarter 2025 (Q2 2025), -19% from a year earlier and -0.6% from the quarter before.
Was Xenetic Biosciences profitable in the second quarter 2025?
Operating loss was $724K (-122.8% of revenue) and net loss $689K.